Who makes raltegravir and cisplatin?

raltegravir and cisplatin is developed by New Mexico Cancer Research Alliance.

What development phase is raltegravir and cisplatin in?

raltegravir and cisplatin is in Phase 1.

Last reviewed 2026-04-20 · How we verify

raltegravir and cisplatin

New Mexico Cancer Research Alliance · Phase 1 active Small molecule Quality 0/100

At a glance

Generic name	raltegravir and cisplatin
Also known as	MK-0518, Isentress, raltegravir, cisplatin, docetaxel
Sponsor	New Mexico Cancer Research Alliance
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Pilot Study of Raltegravir and Cisplatin in Squamous Cell Carcinoma of Head and Neck (EARLY_PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

raltegravir and cisplatin CI brief — competitive landscape report
raltegravir and cisplatin updates RSS · CI watch RSS
New Mexico Cancer Research Alliance portfolio CI